MACE/MACE+ endpoints evaluated across CKD patients not on dialysis and on dialysis Superiority in time to first MACE+ versus epoetin alfa in incident dialysis patients…
5/9/2019
Positive topline results from pooled safety analyses of roxadustat Phase 3 global program Completed one year of treatment in Phase 2 trial evaluating pamrevlumab in…
5/9/2019
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…
4/15/2019
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…
2/27/2019
Connecture, Inc. announces the sales of its Commercial U65 business unit to Benefitfocus With the sale of the U65…
2/26/2019
Crossmatch®, part of HID Global, today announced its fingerprint reading technology is enabling secure identity management on the newly revealed Lenovo ThinkPad T490 Healthcare Edition.…
2/12/2019
